0000000000377253

AUTHOR

M. Ceccanti

showing 2 related works from this author

The Belle II vertex detector integration

2019

Belle II DEPFET, PXD, and SVD Collaborations: et al.

Nuclear and High Energy PhysicsPhysics::Instrumentation and DetectorsSilicon sensorPhase (waves)Computer Science::Computational Geometry7. Clean energy01 natural scienceslaw.inventionNuclear physicsBelle II; Data acquisition; Pixel detector; Silicon sensor; Strip detector; Vertex detector; Nuclear and High Energy Physics; InstrumentationData acquisitionlaw0103 physical sciencesVertex detectorBelle IIStrip detectorColliderInstrumentationNuclear and High Energy PhysicPhysicsInterconnectionPixel010308 nuclear & particles physicsDetectorBelle II; data acquisition; pixel detector; silicon sensor; strip detector; vertex detectorData acquisitionPixel detectorUpgradeHigh Energy Physics::ExperimentFocus (optics)Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment
researchProduct

Effect of RNS60 in amyotrophic lateral sclerosis: a phase II multicentre, randomized, double-blind, placebo-controlled trial

2022

Background and purpose: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with limited treatment options. RNS60 is an immunomodulatory and neuroprotective investigational product that has shown efficacy in animal models of ALS and other neurodegenerative diseases. Its administration has been safe and well tolerated in ALS subjects in previous early phase trials. Methods: This was a phase II, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial. Participants diagnosed with definite, probable or probable laboratory-supported ALS were assigned to receive RNS60 or placebo administered for 24 weeks intravenously (375 ml) once a week and via nebul…

treatmentAmyotrophic Lateral Sclerosisplacebo-controlledNeurodegenerative DiseasesALS; clinical trial; placebo-controlled; randomized; treatmentclinical trialTreatment OutcomeNeurologyDouble-Blind MethodrandomizedQuality of LifeHumansSettore MED/26 - NeurologiaNeurology (clinical)ALSBiomarkers
researchProduct